您的位置: 首页 » 法律资料网 » 法律法规 »

Provisions for Drug Advertisement Examination

作者:法律资料网 时间:2024-05-20 09:08:57  浏览:9348   来源:法律资料网
下载地址: 点击此处下载

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


下载地址: 点击此处下载

滞销音像产品报废损失会记处理办法

广电部


滞销音像产品报废损失会记处理办法

1988年11月11日,广播电影电视部

根据《国营音像企业成本管理实施细则》(以下简称《实施细则》第二十七条第三款,现就具体会计帐务处理暂作如下统一规定:
一、每月采取合并按月预提提成价差的办法。以库存音像产品总定价的5‰为标准。列入商品流通费。并在预提费用科目下设置二级科目报损备用金额以反映。分录:
借:商品流通费-商品损耗
贷:预提费用-报损备用金
二、滞销音像产品损失部分应扣除保留残值及冲减已提版费后。在预提的提成差价中列支。分录:
借:产成品-处理品
预提费用-编录出版费
预提费用-报损备用金
贷:产成品
每年年底库存音像产品盘点后。仓库应将库存音像产品按出版,发行分年详细列明。报送财务部门。以便财务部门根据《实施细则》所列比例考核滞销音像产品损失的列支情况。
三、如果应列支的损失数大于帐面结存的提成差价数。其差额应一次补提。用蓝字计入商品流通费。如应列支的损失数小于帐面结存数。其差额应全部用红字冲减商品流通费。分录:
借:商品流通费-商品损耗
贷:预提费用-报损备用金


淮北市人民政府办公室转发安徽省人民政府办公厅关于印发安徽省政府信息发布保密审查暂行办法的通知

安徽省淮北市人民政府办公室


淮北市人民政府办公室转发安徽省人民政府办公厅关于印发安徽省政府信息发布保密审查暂行办法的通知
淮政办〔2008〕56号


濉溪县、各区人民政府,市政府各部门、各直属机构:

现将《安徽省人民政府办公厅关于印发安徽省政府信息发布保密审查暂行办法的通知》(皖政办〔2008〕11号)转发给你们,并结合我市实际提出以下要求,请一并贯彻执行。

一、提高保密审查意识。各级行政机关要深入学习《中华人民共和国保守国家秘密法》、《中华人民共和国政府信息公开条例》以及其他相关法律、法规和规定,切实提高领导干部和工作人员对政府信息发布保密审查工作的保密审查意识。

二、建立工作机制。各级行政机关应当确定政府信息发布保密审查工作机构,建立健全政府信息发布保密审查制度,严格履行政府信息发布保密审查程序,各项工作职责要落实到人。

三、加强督促检查。各级保密工作部门要对各单位贯彻执行《安徽省政府信息发布保密审查暂行办法》的工作进行指导、监督和检查。

淮北市人民政府办公室
二○○八年五月二十日

安徽省人民政府办公厅关于印发安徽省政府信息发布保密审查暂行办法的通知
皖政办〔2008〕11号

各市、县人民政府,省政府各部门、各直属机构:

省国家保密局、省政务公开办制定的《安徽省政府信息发布保密审查暂行办法》已经省政府同意,现印发给你们,请认真贯彻执行。

安徽省人民政府办公厅
二○○八年三月十四日

安徽省政府信息发布保密审查暂行办法

第一条 为保证公民、法人和其他组织依法获取政府信息,根据《中华人民共和国保守国家秘密法》、《中华人民共和国政府信息公开条例》(以下称《条例》)以及其他相关法律法规和国家有关规定,并结合我省实际,制定本办法。

第二条 本办法适用于行政机关对拟公开政府信息的保密审查。

第三条 行政机关在公开政府信息前,应当依照《中华人民共和国保守国家秘密法》以及其他相关法律法规和国家有关规定对拟公开的政府信息进行保密审查。
政府信息发布保密审查应遵循谁公开谁审查、谁审查谁负责和先审查后公开的原则。

第四条 行政机关政府信息公开工作机构负责组织协调政府信息发布保密审查工作。
行政机关确定的政府信息发布保密审查工作机构(以下称保密审查机构)承担以下职责:
(一)对本机关拟公开政府信息进行保密审查;
(二)对政府信息是否可以公开等不确定事项的申报;
(三)对政府信息发布保密审查工作的统计、分析和报告等。

第五条 行政机关保密工作机构在政府信息公开工作中的主要职责:
(一)制定本机关信息发布保密审查制度,并负责督促落实;
(二)对已泄密或可能泄密的政府信息采取补救措施;
(三)负责查处本机关或督促查处本系统发生的泄密事件,协助保密工作部门查处重大泄密事件。

第六条 各级保密工作部门应当加强对政府信息发布保密审查工作的指导、监督和检查,在政府信息公开工作中履行以下职责:
(一)开展行政机关工作人员保密教育和培训,指导和督促行政机关建立、落实政府信息发布保密审查制度;
(二)受理行政机关提出的政府信息是否属于国家秘密事项的申请;
(三)开展保密检查,督促有关机关查处信息公开过程中泄密事件,直接查处或组织查处重大泄密事件。

第七条 行政机关发布政府信息前应由信息提供部门提出审查意见,经机关保密审查机构审查后,报机关主管领导批准。对保密审查不能公开的政府信息,应说明理由。保密审查记录应保存备查。
行政机关在信息形成或公文制作程序中应增加确定信息是否公开以及以何种方式公开的程序。具体承办人员应当对照国家秘密及其密级具体范围的规定和其他要求,确定其是否可以公开,并履行保密审查程序。
行政机关对《条例》施行前尚未公开的政府信息,应履行保密审查程序。

第八条 行政机关拟公开其他机关尚未公开的信息,应当经信息产生部门批准,未经批准不得擅自公开。法律、法规、规章另有规定的除外。

第九条 行政机关拟公开保密期限届满的国家秘密信息,应按照有关保密规定进行审查后确定是否可以公开。

第十条 行政机关拟公开涉及公共卫生、重大动物疫情、统计信息、重要地理信息数据等需要审批的政府信息时,应按照相关法律、法规和国家有关规定确定的审批权限报请审批。

第十一条 行政机关依申请公开政府信息,应由机关保密审查机构进行保密审查。

第十二条 行政机关对政府信息不能确定是否可以公开时,由保密审查机构依照法律、法规和国家有关规定报有关主管部门或者同级保密工作部门确定。
接到申请的有关主管部门或保密工作部门,应在十个工作日内作出能否公开的批复。

第十三条 行政机关未经保密审查,公开不应当公开的信息,一经发现,应当及时采取补救措施。造成泄密的,有关部门应组织查处。

第十四条 公民、法人或其他组织认为行政机关以保密为由,不履行公开义务或者在政府信息公开工作中保密审查行为侵犯其合法权益的,可依法申请行政复议或提起行政诉讼。

第十五条 行政机关未建立政府信息发布保密审查制度,由同级监察机关、保密工作部门、上一级行政机关责令改正;情节严重的,对行政机关主要负责人依法给予处分。

第十六条 行政机关有下列行为之一的,由同级监察机关、保密工作部门、上一级行政机关追究相关责任人的行政责任;构成犯罪的,依法追究刑事责任:
(一)对拟公开的信息审查不当,造成泄密的,应追究信息发布审批人、提供信息部门负责人和直接责任人的责任;
(二)保密审查机构未履行保密审查职责,造成泄密的,应追究保密审查机构负责人和直接责任人的责任。

第十七条 行政机关应将信息发布保密审查纳入本单位、本系统保密管理工作的重要内容。
各级保密工作部门应将信息发布保密审查纳入保密工作目标管理考核内容。
对在信息发布保密审查工作中做出突出成绩的集体和个人,应给予表彰和奖励。

第十八条 法律、法规授权的具有管理公共事务职能的组织,其信息发布保密审查适用本办法。
教育、医疗卫生、计划生育、供水、供电、供气、供热、环保、公共交通等与人民群众利益密切相关的公共企事业单位,其信息发布保密审查参照本办法执行。

第十九条 法律、法规关于政府信息发布保密审查另有规定的,从其规定。

第二十条 本办法由省国家保密局负责解释。

第二十一条 本办法自2008年5月1日起施行。